Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2016

View Archived Issues

Genentech initiates phase I trial of GDC-0134 in patients with ALS

Worldwide collaborations to control recent Zika virus outbreaks / News in Context

Researchers identify germline variants associated with melanoma prognosis

FDA approves Athenex's IND application for oradoxel

FDA accepts BLA submission for brodalumab in moderate to severe plaque psoriasis

Ixchelsis reports positive phase IIa results for IX-01 as treatment of premature ejaculation

Domainex and Cresset Discovery Services form alliance

Alkermes begins phase I clinical testing of ALKS-7119

FDA accepts for review cardiovascular outcomes data for Jardiance

Phase IIa study of GLPG-1205 in ulcerative colitis does not meet efficacy endpoints

Steba completes phase III trial of Tookad, submits MAA

Biomarkers linked to metastasis of endometrial and lung tumors

OncoMed unblinds phase II trial of tarextumab following DSMB analysis

Shire resubmits NDA for lifitegrast for dry eye disease

Results from part A of MoveDMD trial of CAT-1004 support progression to part B

WuXi Healthcare Ventures invests in Twist Bioscience and Syros Pharmaceuticals

Pharmaceutical industry calls for government collaboration to fight antibiotic resistance

Polish institutions report 5-HT/dopamine receptor modulators

Moberg Pharma issues a 5-year senior unsecured bond loan

Sunshine Lake Pharma discloses JAK3 inhibitors

Novartis reports soluble guanylate cyclase activators

Galapagos and Gilead Sciences file transparency notification

New animal model designed to reproduce ischemia in head and neck surgery

3D-printed biomimetic tympanic membrane shows similar acoustic properties to human eardrum

Tissue-engineered cartilage shows promise for laryngotracheal reconstruction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...